The founders


Nicolas Chanut

Nicolas is Vertidiag’s CEO. He is a former student of Sciences Po Paris, and is now a doctoral researcher in economics at the London School of Economics (UK). He specialises in the fields of public economics and innovation. He has received a scholarship from the Economic and Social Research Council, and is also a Teaching Fellow in the Department of Economics where he teaches empirical methods and public economics.

Six years ago, a family member experienced a small stroke in the ear area, causing her to instantly lose all sense of balance for several weeks. This episode left a lasting impression on Nicolas, and he sees in Vertidiag the opportunity to provide relief to hundreds of thousands of people, who suffer from similar pathologies and who today have no access to any treatment.

Christian Chabbert

Christian Chabbert


Christian (PhD, HDR) is a scientific advisor to Vertidiag. Christian is currently a CNRS research fellow, leading the team Physiopathology and Vestibular Disorders Therapy (UMR7260 CNRS-AMU) and founder of GDR Vertige.

After a thesis at the University of Montpellier, Christian did a postdoc in the laboratory of Pr AJ Hudspeth at the Southwestern Medical Center in Dallas (USA), and then at the Rockefeller Institute in New York (USA). In 1997, Christian joined the CNRS (French National Center for Scientific Research) and the Institute of Neurosciences in Montpellier, France. Since 2014, Christian is part of the laboratory of Integrative and Adaptive Neurosciences at the University of Aix Marseille (UMR7260 CNRS-AMU).  He has published 48 articles in different scientific journals. Since 2015, Christian is founder and director of GDR Vertige, a national federative group that brings together scientists, clinicians and industrialists involved in vertigo research ( He has filed 4 patents with INSERM covering different aspects of his research.

In 2009, Christian co-founded Sensorion, a biotechnology company based in Montpellier.

Michel Kaczorek

Michel is a member of Vertidiag’s Board. After a PhD in oncology (ICIG, Villejuif) and in microbiology (Groupement de Génie Génétique, Institut Pasteur), and after 22 years in R&D of therapeutic recombinant proteins at Institut Pasteur, Harvard Medical School and Pasteur Vaccines, he co-founded, as Scientific Director, Protéine Performance SA, then founded Synt:em SA of which he was President until 2005. He then provided strategic support for the creation of innovative healthcare companies via the BioTop accelerators (Institut Pasteur) and INSERM-Transfert Initiative. Between 2008 and 2018, he was Project Director of the Eurobiomed Competitiveness Cluster. Michel participated in the creation and financing of six companies of which he was co-founder or director. Until 2018, he was Chairman of Kephalios SA, specialized in implantable cardiac medical devices. 

Since 2011, Michel has been Chairman of the investment fund “Holding Incubatrice 2” (Truffle Capital). He is still a member of the Strategic Project Board of Eurobiomed and of the Investment Committee of the SATT AxLR accelerator. He published more than forty publications, issued 9 patents issued and was instrumental in raising more than 50M Euros from private investors.

Brahim Tighilet


Brahim (PhD, HDR) is a scientific advisor to Vertidiag. He is also a Senior Lecturer at Aix-Marseille University. He obtained his PhD at Aix-Marseille University in 1995, then did a postdoctoral fellowship in the College of Medicine at the University of Irvine in California (USA), in the laboratory of Prof. Edward G. Jones. His expertise in the field of vestibular compensation is internationally recognized by academics and clinicians alike. He has been conducting his research in the Sensory and Cognitive Neuroscience Laboratory of the UMR 7260 of the CNRS. His research focuses on the physiopathology of vestibular disorders. Among other discoveries, he was the first to demonstrate the existence of post-injury neurogenesis (birth of new neurons) in an experimental model of vestibular function plasticity, as well as its beneficial role in restoring static and dynamic equilibrium functions.

For several years, he has developed an ongoing partnership with the pharmaceutical industry in the field of neuropharmacology of vertigo. In particular, his work has enabled him to demonstrate for the first time the mechanisms and sites of action of betahistine in an animal model of vestibular pathology. He has published 40 articles in various scientific journals and book chapters. Since 2019, Brahim is president of the GDR Vertidiag. He has filed with the CNRS 2 patents on anti-vertigo pharmacological compounds.

The team

Vertidiag’s almost entire team in January 2020 at Wereso. © 2020 Weréso Marseille